Peptide Coupling Reagents Selection Guide | Sigma …
Peter has worked at the forefront of Fmoc solid phase peptide synthesis since gaining his PhD in 1985 at the University of Exeter. At LKB Biochrom he helped develop the first fully automated, continuous flow peptide synthesiser and later, at Merck, he has been instrumental in the development of the Novabiochem peptide and combinatorial reagent catalogue.
The Novabiochem® brand offers one ..
Stephen joined Sygnature in January 2016 from Hitgen where he was VP Business Development; establishing several early research collaborations for this Chinese CRO start-up. Prior to Hitgen he held business development positions at Pharmacia, Novabiochem and Protherics. He is a highly-experienced Medicinal Chemist and has worked in a broad range of therapeutic areas within small and large discovery organisations including MSD, Proteus, Tularik, Amgen and, most recently, Vertex, where he led the Discovery Chemistry department in the UK. Stephen has a BSc (Hons.) in chemistry and a PhD in medicinal chemistry from the University of Nottingham, and undertook post-doctoral research at the University of Edinburgh in the area of peptide synthesis methodology.
As Novabiochem’s R&D Manager, he has worked on some of the principle enabling technologies in the field of Fmoc chemistry. He has pioneered the use of derivatives for the production of long and complex peptides and is responsible for (Merck Millipore) Novabiochem’s worldwide technical marketing and support which gives him a wealth of experience in solving synthetic problems.